Performance History
| Key Stats | |
|---|---|
| Open | $2.13 |
| Prev. Close | $2.02 |
| EPS | -4.08 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | 10712454.00 |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 2.13 | 2.13 |
| 52 Week Range | 0.84 | 2.99 |
| Ratios | |
|---|---|
| P/B Ratio | 5.43 |
| Revenue | - |
| Operating M. % | -33,911.77% |
| Earnings | $0.00 |
| Earnings Growth % | 11.84% |
| EBITDA Margin % | - |
| ROEÂ % | -302.20% |
| EPS | -4.08 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
All Score 38 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| ERNA | MARKET | |
|---|---|---|
| Value | 45 | 38 |
| Quality | 24 | 40 |
| Ownership | 23 | 17 |
| Growth | 31 | 46 |
| Dividends | - | 37 |
Eterna Therapeutics's Price discount from all time high of 99.99% is great compared to market average of 41.59%. This indicates ERNA could be a good value stock.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Eterna Therapeutics (ERNA)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Matthew Angel Ph.D.
- Headquarters
- Cambridge
- Employees
- 9
- Exchange
- NASDAQ
Keep an eye on Eterna Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is Eterna Therapeutics's (ERNA) price per share?
The current price per share for Eterna Therapeutics (ERNA) is $2.13. The stock has seen a price change of $0.11 recently, indicating a 5.45% change. This reflects the stock's recent market performance and investor sentiment.
What is the 52-week high and low for Eterna Therapeutics (ERNA)?
For Eterna Therapeutics (ERNA), the 52-week high is $2.99, which is 40.38% from the current price. The 52-week low is $0.84, the current price is 153.57% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
Is Eterna Therapeutics (ERNA) a growth stock?
Eterna Therapeutics (ERNA) has shown an average price growth of 0.41% over the past three years. It has received a score of -3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Eterna Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
What is Eterna Therapeutics (ERNA) stock price performance year to date (YTD)?
As of the latest data, Eterna Therapeutics (ERNA) has a year-to-date price change of 13.3%. Over the past month, the stock has experienced a price change of -4.91%. Over the last three months, the change has been 23.84%. Over the past six months, the figure is 85.22%.
Is Eterna Therapeutics (ERNA) a profitable company?
Eterna Therapeutics (ERNA) has a net income of -$21.67M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -33.91K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$20.67M. Furthermore, the EBITDA is -$20.59M.
What is the market capitalization of Eterna Therapeutics (ERNA)?
Eterna Therapeutics (ERNA) has a market capitalization of $10.71M. The average daily trading volume is 6.13K, indicating the stock's liquidity and investor engagement.
News
Microsoft Leads in Carbon Dioxide Removal (CDR) Credit Purchases, Acquiring 6.6M Tonnes, Surpassing All Other Buyers Combined
SoftBank’s Profitability Surges Amid AI Investment Boom
Revolut Hit 26 Million Downloads in 2023, 65% more than a Year Before
US Smartphone Sales to Grow by Only 3% by 2028, 7x Less than in the Chinese Market
Xiaomi and Samsung Smartphones Identified Among Top Radiation Emitters in 2024
Traders Pile Up Short Positions as Grayscale Abandons Ethereum Futures ETF Plan
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.